A phase I-II study of COX-2 inhibitor, Celebrex (Celecoxib) and chemoradiation in patients with locally advanced cervical cancer: Primary endpoint analysis of RTOG 0128

被引：2
|
作者：
Gaffney, DK
Winter, K
Dicker, A
Miller, B
Jhingran, A
Ryu, J
Avizonis, V
Fromm, M
Greven, K
机构：
[1] Univ Utah, Salt Lake City, UT USA
[2] RTOG, Philadelphia, PA USA
[3] Thomas Jefferson Univ, Philadelphia, PA 19107 USA
[4] Wake Forest Univ, Winston Salem, NC 27109 USA
[5] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[6] Univ Calif Davis, Sacramento, CA 95817 USA
[7] LDS Hosp, Salt Lake City, UT USA
[8] Akron Gen Med Ctr, Akron, OH USA
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2005年 / 63卷 / 02期
关键词：
D O I：
10.1016/j.ijrobp.2005.07.161
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
155
引用
收藏
页码：S93 / S94
页数：2
相关论文
共 50 条
  • [41] Weekly carboplatin and docetaxel for locally advanced primary and recurrent cervical cancer:: A phase I study
    Rein, DT
    Kurbacher, CM
    Breidenbach, M
    Schöndorf, T
    Schmidt, T
    König, E
    Göhring, UJ
    Blohmer, JU
    Mallmann, P
    GYNECOLOGIC ONCOLOGY, 2002, 87 (01) : 98 - 103
  • [42] A phase I/II study of induction oxaliplatin, 5FU chemoradiation in patients with locally advanced, unresectable pancreatic cancer
    Leung, R. C.
    Ryan, T.
    Hochster, H.
    Newman, E.
    Chandra, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] A phase II trial of TGFβ type I receptor inhibitor, galunisertib, plus neoadjuvant chemoradiation in patients with locally advanced rectal cancer.
    Young, Kristina Hoot
    Gunderson, Andrew J.
    Gilchrist, Miranda
    Whiteford, Mark
    Kiely, Maria X.
    Hayman, Amanda
    O'Brien, David P.
    Ahmad, Rehan
    Manchio, Jeffrey V.
    Brosnan, Evelyn
    Vaccaro, Gina M.
    Li, Rui
    Simon, Miklos
    McCormick, Mary
    Drokin, Ashley
    Cramer, Julie
    Urba, Walter John
    Gough, Michael
    Crittenden, Marka R.
    Yamazaki, Tomoko
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [44] Neoadjuvant use of 5-fluorouracil, epirubicin and cyclophosphamide with and without celecoxib for locally advanced breast cancer: A phase II study correlating response to celecoxib with high levels of COX-2 gene expression in the tumor.
    Chow, LW
    Toi, M
    Takebayashi, Y
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 860S - 860S
  • [45] Locally advanced cervical cancer - neoadjuvant chemotherapy followed by concurrent chemoradiation and targeted therapy as maintenance: A phase II study
    Benson, Rony
    Pathy, Sushmita
    Kumar, Lalit
    Mathur, Sandeep
    Dadhwal, Vatsla
    Mohanti, Bidhu Kalyan
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2019, 15 (06) : 1359 - 1364
  • [46] A study of weekly CPT-11 in association with COX-2 inhibitor celecoxib in pretreated metastatic colorectal cancer patients
    Vaghi, M.
    Ardizzoia, A.
    Bignami, A.
    Brivio, F.
    Lissoni, P.
    Gardani, G.
    ANNALS OF ONCOLOGY, 2005, 16 : 46 - 46
  • [47] Phase I-II Study of Denileukin Diftitox (ONTAK®) in Patients with Advanced Refractory Breast Cancer
    Salazar, L. G.
    Higgins, D.
    Childs, J.
    Bates, N.
    Dang, Y.
    Slota, M.
    Coveler, A. L.
    Waisman, J. R.
    Disis, M. L.
    CANCER RESEARCH, 2009, 69 (24) : 750S - 751S
  • [48] Phase I-II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer
    Gil-Delgado, MA
    Antoine, EC
    Guinet, F
    Bassot, V
    Grapin, JP
    Benhammonda, A
    Adam, R
    Castaing, D
    Bismuth, H
    Khayat, D
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2001, 24 (03): : 251 - 254
  • [49] Phase I-II study of irinotecan hydrochloride combined with cisplatin in patients with advanced gastric cancer
    Shirao, K
    Shimada, Y
    Kondo, H
    Saito, D
    Yamao, T
    Ono, H
    Yokoyama, T
    Fukuda, H
    Oka, M
    Watanabe, Y
    Ohtsu, A
    Boku, N
    Fujii, T
    Oda, Y
    Muro, K
    Yoshida, S
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (03) : 921 - 927
  • [50] Docetaxel, cisplatin and 5-fluorouracil in patients with locally advanced unresectable head and neck cancer: a phase I-II feasibility study
    Schrijvers, D
    Van Herpen, C
    Kerger, J
    Joosens, E
    Van Laer, C
    Awada, A
    Van den Weyngaert, D
    Nguyen, H
    Le Bouder, C
    Castelijns, JA
    Kaanders, J
    De Mulder, P
    Vermorken, JB
    ANNALS OF ONCOLOGY, 2004, 15 (04) : 638 - 645
12345